Filing search / Inhibrx Biosciences, Inc. / "Reputation"

DEFM14A

INBX Inhibrx Biosciences, Inc.

26 Apr 24

Proxy related to merger

4:06pm

adjusted and present-value basis. with the Company, their reputation as an internationally recognized investment banking firm and their substantial … . Given the business reputation and global capabilities of Parent, and the Board of Directors’ perception that Parent is willing to devote the resources

DEFA14A

INBX Inhibrx Biosciences, Inc.

6 Feb 24

Additional proxy soliciting materials

4:30pm

the possibility of insider trading and to prevent any appearance of impropriety or unfair advantage that may damage the Company’s reputation. Q2: When

DEFA14A

INBX Inhibrx Biosciences, Inc.

23 Jan 24

Additional proxy soliciting materials

6:38am

successor Rights Agent who shall be a stock transfer agent of national reputation or the corporate trust department of a commercial bank

8-K

EX-2.1

i5tkbc0c

23 Jan 24

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

6:35am

8-K

EX-2.2

ihta04l

23 Jan 24

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

6:35am

10-K

co7rf h4o6y

12 Mar 21

Annual report

8:46am

10-Q

fz1mblmpfr3t3

13 Nov 20

Quarterly report

4:09pm

424B4

y8cuqwg9m6g hy

19 Aug 20

Prospectus supplement with pricing info

5:21pm

DRS

neq87bvaj6pxcxribri

26 Jun 20

Draft registration statement

12:00am

S-1

8787b6d40c

3 Jun 19

IPO registration

4:17pm

S-1

EX-10.24

qxn1oj4db u3

3 Jun 19

IPO registration

4:17pm

DRS/A

EX-10.24

mqko7p 8ifbvxtaid

22 Feb 19

Draft registration statement (amended)

12:00am

DRS/A

jeeany08r1qmva5a98

22 Feb 19

Draft registration statement (amended)

12:00am

DRS

d7w67m8pm44 mb

7 Jan 19

Draft registration statement

12:00am